title: Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.
abstract: OBJECTIVE
  Immune events sustaining dendritic cell (DC)-dependent epitope spreading (ES) are of key relevance to the development of relapses during multiple sclerosis (MS). Although no drugs are currently available to target ES, its inhibition would represent a major advancement in MS therapy. Inhibitors of the enzyme PARP-1 afford protection in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE). These drugs epigenetically impair antigen presentation by DCs, but whether these drugs affect ES is unknown. Here, we investigated whether short-term treatments with these compounds would impair ES, thereby preventing EAE relapses.
  
  
  METHODS
  We used a model of relapsing EAE in SJL mice and also adopted in vivo and ex vivo models of DC-dependent T-cell polarization. The effect of PARP-1 inhibitors on ES was evaluated at the humoral and cellular level.
  
  
  RESULTS
  Short-term treatments with PARP-1 inhibitors during the acute phase of relapsing EAE of mice induced, at later times, more tolerogenic DCs, increased numbers of Treg cells and impairment of ES at the humoral and cellular level. These effects are followed by long-lasting reduction of relapse severity and incidence, although drug treatment had been discontinued for several weeks. PARP-1 inhibitors also induced tolerogenic DCs and increased Treg cells number and function in a model of ovalbumin immunization.
  
  
  CONCLUSIONS
  Our data emphasize the therapeutic potential of PARP-1 inhibitors in the treatment of relapsing-remitting MS and additional ES-driven autoimmune disorders.
authors.forename: L
authors.initials: L
authors.lastname: Cavone
authors.forename: B
authors.initials: B
authors.lastname: Peruzzi
authors.forename: R
authors.initials: R
authors.lastname: Caporale
authors.forename: A
authors.initials: A
authors.lastname: Chiarugi
mesh_terms: D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000939:Epitopes / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D010047:Ovalbumin / Q000276:immunology; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012008:Recurrence; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D004791:Enzyme Inhibitors; D000939:Epitopes; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D010047:Ovalbumin; C499321:Parp1 protein, mouse; D000071137:Poly (ADP-Ribose) Polymerase-1
references.citation: Immunology. 1989 Jun;67(2):258-62
references.pmid: 2502498
references.citation: Trends Mol Med. 2012 Feb;18(2):92-100
references.pmid: 22078487
references.citation: Nat Rev Immunol. 2002 Feb;2(2):85-95
references.pmid: 11910899
references.citation: J Neuroimmunol. 2001 Jul 2;117(1-2):78-86
references.pmid: 11431007
references.citation: Curr Opin Cell Biol. 2008 Jun;20(3):294-302
references.pmid: 18450439
references.citation: Arch Immunol Ther Exp (Warsz). 2000;48(5):347-51
references.pmid: 11140461
references.citation: Nat Rev Drug Discov. 2013 Jan;12(1):51-63
references.pmid: 23274471
references.citation: J Neurosci Res. 2005 Jul 15;81(2):190-8
references.pmid: 15931673
references.citation: Trends Immunol. 2002 Sep;23(9):445-9
references.pmid: 12200066
references.citation: J Biol Chem. 1992 Jan 25;267(3):1569-75
references.pmid: 1530940
references.citation: Nat Rev Drug Discov. 2005 May;4(5):421-40
references.pmid: 15864271
references.citation: Br J Pharmacol. 2002 Nov;137(6):761-70
references.pmid: 12411406
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1053-61
references.pmid: 15159442
references.citation: Mol Cell. 2010 Jul 9;39(1):8-24
references.pmid: 20603072
references.citation: J Immunol. 2007 Jul 1;179(1):305-12
references.pmid: 17579050
references.citation: Cell. 2003 Jun 13;113(6):677-83
references.pmid: 12809599
references.citation: PLoS One. 2013 Aug 19;8(8):e71590
references.pmid: 23977081
references.citation: Nat Immunol. 2009 Sep;10(9):958-64
references.pmid: 19684606
references.citation: Int J Immunopharmacol. 1995 Apr;17(4):265-71
references.pmid: 7672878
references.citation: J Immunol. 2010 Apr 1;184(7):3470-7
references.pmid: 20208002
references.citation: Br J Pharmacol. 2010 Aug;160(7):1577-9
references.pmid: 20649561
references.citation: CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49
references.pmid: 21205831
references.citation: Biochim Biophys Acta. 1989 Nov 2;1009(2):185-7
references.pmid: 2508750
references.citation: Trends Pharmacol Sci. 2002 Mar;23(3):122-9
references.pmid: 11879679
references.citation: Mult Scler. 2011 Jul;17(7):794-807
references.pmid: 21343230
references.citation: Br J Pharmacol. 2010 Aug;160(7):1573-6
references.pmid: 20649560
references.citation: Nat Med. 2005 Mar;11(3):335-9
references.pmid: 15735651
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: N Engl J Med. 2007 Aug 30;357(9):851-62
references.pmid: 17660530
references.citation: J Neuroimmunol. 2010 Mar 30;220(1-2):52-63
references.pmid: 20149931
references.citation: Immunol Rev. 2011 May;241(1):206-27
references.pmid: 21488899
references.citation: Nat Immunol. 2007 Feb;8(2):172-80
references.pmid: 17206145
references.citation: Int Rev Immunol. 2010 Apr;29(2):111-8
references.pmid: 20367138
references.citation: Immunol Lett. 2004 Jun 15;94(1-2):11-26
references.pmid: 15234530
references.citation: Immunol Rev. 1998 Aug;164:63-72
references.pmid: 9795764